web analytics
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Cancer
    • COVID-19
    • Balstilimab
      anti-PD-1
    • Zalifrelimab
      anti-CTLA-4
    • Botensilimab
      Multipurpose, 2nd Gen CTLA-4
    • AGEN1327
      anti-TIGIT
    • AGEN1777
      anti-TIGIT bispecific
    • AGEN2373
      anti-CD137
    • AGENT-797
      Allogeneic iNKT cell Therapy
  • Capabilities
    • Discovery and Development
    • GMP Manufacturing Facility
    • Clinical Development
  • Publications
    • Publications and Presentations
    • Newsletters
  • Investors
    • Overview
    • Press releases
    • Events and Presentations
    • Stock
    • SEC Filings
    • Analyst Coverage
    • Media Coverage
    • Governance
    • Investor Resources
  • Careers
  • Contact Us
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Cancer
    • COVID-19
    • Balstilimab
      anti-PD-1
    • Zalifrelimab
      anti-CTLA-4
    • Botensilimab
      Multipurpose, 2nd Gen CTLA-4
    • AGEN1327
      anti-TIGIT
    • AGEN1777
      anti-TIGIT bispecific
    • AGEN2373
      anti-CD137
    • AGENT-797
      Allogeneic iNKT cell Therapy
  • Capabilities
    • Discovery and Development
    • GMP Manufacturing Facility
    • Clinical Development
  • Publications
    • Publications and Presentations
    • Newsletters
  • Investors
    • Overview
    • Press releases
    • Events and Presentations
    • Stock
    • SEC Filings
    • Analyst Coverage
    • Media Coverage
    • Governance
    • Investor Resources
  • Careers
  • Contact Us
NL 211104 - Expanding the Potential Benefit of anti-CTLA-4 in Pancreatic Cancer through a Clinical Collaboration
Links
  • About Us
  • Pipeline
  • Capabilities
  • Investors
  • Publications

Agenus Inc.

3 Forbes Road
Lexington, MA 02421-7305

T: 781.674.4400

F: 781.674.4200

© 2022 Agenus Inc. All rights reserved.
  • Privacy Policy
  • Terms and Conditions of Use